Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn) regarding the receipt of "Drug Clinical Trial Approval Notification" for HRS-9821 inhalation powder. The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
July 9, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code: 600276 Stock abbreviation: Hengrui Pharma No.: Lin 2025-100

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement on Obtaining Drug Clinical Trial Approval Notification

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Guangdong Hengrui Pharmaceuticals Co., Ltd. (廣東恒瑞醫藥有限公司), a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company"), received the "Drug Clinical Trial Approval Notification" for HRS-9821 Inhalation Powder approved and issued by the National Medical Products Administration (the "NMPA"), and a clinical trial will be conducted in the near future. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Common name of drug: HRS-9821 Inhalation Powder

Dosage Form: Inhalation

Application Matter: Clinical Trial

Application Number: CXHL2500377

Approval Conclusion: In accordance with the Drug Administration Law of the People's Republic of China and the relevant regulations, upon review, the clinical trial application of HRS-9821 Inhalation Powder accepted on April 10, 2025 complies with the relevant requirements for drug registration, and approval is granted for the implementation of this product for the clinical trial of chronic obstructive pulmonary

disease (COPD).

II. Other Information of the Drug

HRS-9821 is a small molecule PDE3/PDE4 inhibitor that can effectively inhibit respiratory inflammation and dilate bronchi. It is intended to be used in clinical practice for maintenance therapy of COPD. At present, among similar products worldwide, only Ensifentrine was approved for marketing in the United States in July 2024 for maintenance therapy of COPD. According to the EvaluatePharma database, the annual sales of Ensifentrine in 2024 was approximately USD 42.00 million. To date, the total accumulated R&D investment in the HRS-9821 project is approximately RMB 38.43 million.

III. Risk Warning

According to the requirements of laws and statutes related to drug registration in China, after obtaining the drug clinical trial approval notification, the drug still needs to be tested in clinical trials and be reviewed and approved by the NMPA before it can be produced for marketing. For a medicinal product, the cycle comprising development, clinical trial approval and production is long and involves many steps. Medicinal product R&D and marketing are easily influenced by some uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks. The Company will actively promote the aforementioned R&D project in accordance with the relevant national stipulations, and promptly perform the information disclosure obligation for the subsequent progress of the project.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

July 8, 2025